(RTTNews) - On Thursday, Eli Lilly and Company (LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing that Foundayo was associated with significant reductions in predicted 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or over
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.